FOLH1 and prostate carcinoma: Current efforts on targeted radio-ligand delivery in prostate cancer are centered on prostate-specific membrane antigen (PSMA) for the adenocarcinoma subtype using anti-PSMA antibodies (e.g., 177Lu-J591 and 225Ac-J591), or radio-labeled small molecule PSMA-617 (e.g., 177Lu-PSMA-617 [9, 10], 225Ac-PSMA-617 and 212Pb-PSMA-617 [11, 12]).